• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Front-line treatment of multiple myeloma.多发性骨髓瘤的一线治疗
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000242. eCollection 2019 Jun.
2
Which therapies will move to the front line for multiple myeloma?哪些疗法将成为多发性骨髓瘤的一线治疗方案？
Expert Rev Hematol. 2017 May;10(5):383-392. doi: 10.1080/17474086.2017.1317589. Epub 2017 Apr 24.
3
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.硼替佐米作为一线治疗多发性骨髓瘤患者的疗效。
Clin Med Insights Oncol. 2013;7:53-73. doi: 10.4137/CMO.S7764. Epub 2013 Feb 28.
4
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.老年多发性骨髓瘤患者接受新型药物联合一线治疗后的复发模式及预后
Leuk Res Rep. 2015 Sep 24;4(2):64-9. doi: 10.1016/j.lrr.2015.09.002. eCollection 2015.
5
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.卡非佐米和泊马度胺：多发性骨髓瘤治疗的最新进展
Pharmacotherapy. 2014 Sep;34(9):927-40. doi: 10.1002/phar.1463. Epub 2014 Jul 19.
6
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.硼替佐米、来那度胺和地塞米松联合帕比司他用于适合移植的多发性骨髓瘤患者的一线治疗：一项1期试验。
Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.
7
Bortezomib in the front-line treatment of multiple myeloma.硼替佐米用于多发性骨髓瘤的一线治疗。
Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053.
8
Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.真实世界中老年多发性骨髓瘤患者一线治疗疗效和临床结局：中国多中心回顾性研究。
Cancer Med. 2023 Feb;12(3):3101-3111. doi: 10.1002/cam4.5234. Epub 2022 Oct 21.
9
Front-line treatment in younger patients with multiple myeloma.年轻多发性骨髓瘤患者的一线治疗
Semin Hematol. 2009 Apr;46(2):118-26. doi: 10.1053/j.seminhematol.2009.02.005.
10
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].一项比较硼替佐米联合地塞米松与硼替佐米、表柔比星和地塞米松治疗多发性骨髓瘤患者疗效及安全性的队列研究
Zhonghua Nei Ke Za Zhi. 2016 Sep 1;55(9):689-94. doi: 10.3760/cma.j.issn.0578-1426.2016.09.007.

引用本文的文献

1
Recent Advances in the Treatment of Patients with Multiple Myeloma.多发性骨髓瘤患者治疗的最新进展
Cancers (Basel). 2020 Nov 30;12(12):3576. doi: 10.3390/cancers12123576.

本文引用的文献

1
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.自体移植、巩固和维持治疗多发性骨髓瘤：BMT CTN 0702 试验结果。
J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.
2
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.一线自体移植在多发性骨髓瘤中的利弊：时机之争。
Blood. 2019 Feb 14;133(7):652-659. doi: 10.1182/blood-2018-08-825349. Epub 2018 Dec 26.
3
Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.基于病例的圆桌会议：年轻、健康、新诊断多发性骨髓瘤患者的治疗方法。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103.
4
Treatment approach for young, fit, newly diagnosed multiple myeloma patients.年轻、健康的新诊断多发性骨髓瘤患者的治疗方法
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):97-102. doi: 10.1182/asheducation-2018.1.97.
5
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.从诊断到复发：一位美国血液学家和老年血液学家对老年、不适合治疗的骨髓瘤患者的治疗方法的观点。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):88-96. doi: 10.1182/asheducation-2018.1.88.
6
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.从诊断到复发，老年体弱骨髓瘤患者的治疗方法：一位欧洲血液学家的观点。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):83-87. doi: 10.1182/asheducation-2018.1.83.
7
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.FIRST 试验中多发性骨髓瘤一线治疗的生存结局最终分析。
Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.
8
Elderly patients with multiple myeloma: towards a frailty approach?老年多发性骨髓瘤患者：采用衰弱评估方法？
Curr Opin Oncol. 2017 Sep;29(5):315-321. doi: 10.1097/CCO.0000000000000395.
9
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.来那度胺维持治疗在新诊断的多发性骨髓瘤自体干细胞移植后的应用：一项荟萃分析。
J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.
10
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096.

Front-line treatment of multiple myeloma.

作者信息

Cavo Michele, Tacchetti Paola, Zamagni Elena

机构信息

Seràgnoli Institute of Hematology, Alma Mater Studiorum-Bologna University School of Medicine, S.Orsola-Malpighi Hospital, Bologna, Italy.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000242. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000242
PMID:35309768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925677/
Abstract
摘要